Chronic diseases are common and costly, yet they are also among the most preventable health problems. Comprehensive and accurate disease surveillance systems are needed to implement successful efforts which will reduce the burden of chronic diseases on the U.S. population. A number of sources of surveillance data-including population surveys, cohort studies, disease registries, administrative health data, and vital statistics-contribute critical information about chronic disease. But no central surveillance system provides the information needed to analyze how chronic disease impacts the U.S. population, to identify public health priorities, or to track the progress of preventive efforts. A Nationwide Framework for Surveillance of Cardiovascular and Chronic Lung Diseases outlines a conceptual framework for building a national chronic disease surveillance system focused primarily on cardiovascular and chronic lung diseases. This system should be capable of providing data on disparities in incidence and prevalence of the diseases by race, ethnicity, socioeconomic status, and geographic region, along with data on disease risk factors, clinical care delivery, and functional health outcomes. This coordinated surveillance system is needed to integrate and expand existing information across the multiple levels of decision making in order to generate actionable, timely knowledge for a range of stakeholders at the local, state or regional, and national levels. The recommendations presented in A Nationwide Framework for Surveillance of Cardiovascular and Chronic Lung Diseases focus on data collection, resource allocation, monitoring activities, and implementation. The report also recommends that systems evolve along with new knowledge about emerging risk factors, advancing technologies, and new understanding of the basis for disease. This report will inform decision-making among federal health agencies, especially the Department of Health and Human Services; public health and clinical practitioners; non-governmental organizations; and policy makers, among others.

The Social Security Administration (SSA) uses a screening tool called the Listing of Impairments to identify claimants who are so severely impaired that they cannot work at all and thus immediately qualify for benefits. In this report, the IOM makes several recommendations for improving SSA's capacity to determine disability benefits more quickly and efficiently using the Listings.

Despite being one of the world's biggest killers of women, heart disease is under-diagnosed, under-treated, and under-managed. Why? What is going wrong? Important and ground-breaking, Women and Heart Disease brings our attention to the inadequacies in both the diagnosis and treatment of heart disease in women. Key features: * written by Nanette Wenger and Peter Collins, two of the worlds leading cardiologists * contributions from leaders in women‘s cardiac health * covers all aspects of cardiovascular disease, not just coronary artery disease * fully updated. Building on the success of the best-selling first edition, this is essential reading for all physicians with a particular interest in women and heart disease.

Coronary Artery Disease in Women provides the information physicians must have to successfully diagnose and manage this life-threatening condition. This book discusses the clinically important aspects of coronary artery disease with a focus on gender, age, and race. Coronary Artery Disease in Women is a pioneering work in the field of women's health and a valuable reference for the primary care physician. Part of ACP Women's Health Series.

Discusses the heart and heart disease in terms of incidence, risk factors, prevention, and treatment in women.

Despite media attention and public awareness, recent advances in pharmaceutical and medical developments, heart disease in women is under-diagnosed, under-treated, and under-managed. Many women fail to present in the clinic when symptomatic, because of responsibilities at home or at work. Often the first presentation follows a cardiac event. Women are excluded from many clinical trials regardless of age or cardiac history, simply because most trials are aimed at male patients. This best-selling, updated title, aimed at changing this treatment of women's cardiac issues, covers all aspects of female cardiovascular disease. It is required reading for all practitioners who assess female patients.

This is a groundbreaking book which explains the important clinical and surgical aspects of the diagnosis and treatment of heart disease in women, and seeks to improve the understanding of the difference gender makes to both the presentation of heart disease and the disease itself.